Geftinat Tablet (Gefitinib 250 mg)

Geftinat Tablet (Gefitinib 250 mg)

Geftinat 250 mg Tablets contain Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used in the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Gefitinib targets and blocks the EGFR receptor, which is involved in the growth and spread of cancer cells. By inhibiting EGFR, Gefitinib helps slow down the proliferation of cancer cells, reducing tumor size and improving patient survival rates. It is typically used in patients with advanced or metastatic NSCLC who have specific EGFR mutations.

Geftinat 250 mg Tablets are indicated for:

• Non-Small Cell Lung Cancer (NSCLC): For the treatment of locally advanced or metastatic NSCLC in adults whose tumors have specific EGFR mutations (exon 19 deletions or exon 21 L858R substitution) as detected by an approved diagnostic test.
• First-Line Treatment: For patients with EGFR mutation-positive NSCLC who have not received prior chemotherapy.

Gefitinib works by inhibiting the EGFR tyrosine kinase enzyme, a receptor that, when activated, triggers the growth and division of cancer cells. In NSCLC, mutations in the EGFR gene lead to uncontrolled cell growth. Gefitinib binds to the EGFR, preventing the receptor from activating the intracellular signaling pathways that drive cancer cell proliferation. This results in the inhibition of tumor growth and spread.

• Recommended Dose: The usual dose of Geftinat 250 mg is one tablet once daily.
• Administration: The tablet can be taken with or without food. It should be swallowed whole with a glass of water. It is important to take the medication at the same time each day to maintain steady blood levels.

• Common Side Effects: Diarrhea, acneiform rash, nausea, loss of appetite, and fatigue.
• Serious Side Effects: Interstitial lung disease (ILD), hepatotoxicity, eye problems (e.g., dry eye, irritation), and gastrointestinal perforation. Liver function and lung symptoms should be monitored during treatment.

• Lung Disease: Use caution in patients with a history of lung disease, as Gefitinib may cause or worsen interstitial lung disease (ILD).
• Liver Disease: Patients with liver problems should be monitored closely, as Gefitinib can cause liver toxicity (elevated liver enzymes).
• Pregnancy: Gefitinib is Category D (may harm the fetus). It should be avoided during pregnancy unless the potential benefit justifies the risk.
• Drug Interactions: Gefitinib may interact with drugs that affect the CYP3A4 enzyme, which is involved in its metabolism. Consult your healthcare provider about other medications.

Store Geftinat 250 mg Tablets at room temperature (15°C to 30°C), away from light and moisture. Keep out of reach of children.

Geftinat 250 mg Tablets are a targeted therapy for patients with EGFR mutation-positive non-small cell lung cancer. When used appropriately, Gefitinib helps inhibit tumor growth and improve outcomes in advanced lung cancer. Regular monitoring for side effects, particularly lung and liver function, is essential for safe and effective treatment.